For too long, migraines have been a black spot in medical research. Now sufferers of the condition can have hope after a new antibody treatment developed specifically for migraine prevention has just completed Phase III human clinical trials with remarkably positive results. In the study, respondents reported a 50 percent reduction in monthly migraine days.